Prescription drug · ANDA
Deferasirox NDC 31722-031
Deferasirox 360 mg/1 · Granule · Oral · Camber Pharmaceuticals, Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 31722-031-32 | 3172200313231722003132 | 30 PACKET in 1 CARTON (31722-031-32) / 1 GRANULE in 1 PACKETMarketed from Sep 22, 2022 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Deferasirox
- Generic name (nonproprietary)
- deferasirox
- Active ingredients
- Deferasirox — 360 mg/1
- Dosage form
- Granule
- Route
- Oral
- Labeler
- Camber Pharmaceuticals, Inc.NDC labeler code 31722
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 216229
- Marketing start
- Listing expires
- Other FDA classes
- Cytochrome P450 1A2 Inhibitors (Mechanism)Cytochrome P450 2C8 Inhibitors (Mechanism)Cytochrome P450 3A4 Inducers (Mechanism)Iron Chelating Activity (Mechanism)
- Identifiers
- Product ID 31722-031_17f07dc1-8041-d263-e063-6394a90ae223SPL ID 17f07dc1-8041-d263-e063-6394a90ae223SPL set ID eded6687-ba78-4117-a316-eec56d46a08aRxCUI 1923822, 1923826, 1923828UNII V8G4MOF2V9
- Pharmacologic class
- Iron Chelator
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N431722003132followed by a unit qualifier and the quantityPackage 31722-0031-32. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective . This label includes a boxed warning.
Indications (excerpt from the label)
Deferasirox oral granules are an iron chelator indicated for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older. ( 1.1 ) Deferasirox oral granules are indicated for the treatment of chronic iron overload in patients 10 years of age and older with non-transfusion-dependent thalassemia (NTDT) syndromes, and with a liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram of dry weight (Fe/g dw) and a serum ferritin greater than 300 mcg/L. ( 1.2 ) Limitations of Use: The safety and efficacy of deferasirox oral granules when administered with other iron chelation therapy have not been established. ( 1.3 ) 1.1 Treatment of Chronic Iron Ove…
Excerpt only. Read the full label for complete information.
About NDC 31722-031
- What is NDC 31722-031?
- 31722-031 is the product NDC for Deferasirox, Deferasirox 360 mg/1 granule, listed with the FDA by Camber Pharmaceuticals, Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.
- What drug is associated with this NDC?
- Deferasirox.
- What is the active ingredient?
- Deferasirox.
- Who is the labeler?
- Camber Pharmaceuticals, Inc., NDC labeler code 31722. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for Deferasirox?
- 75 other product NDCs are listed under this name. See all Deferasirox NDCs.
- Is there a related HCPCS / J-code?
- Not in Med-Code's curated HCPCS directory. See Billing references above.
Related NDCs: other Deferasirox products
Other finished products listed under the same name: strengths, forms and labelers.
| Product | Strength | Form · route | Labeler | Product NDC | Package NDCs (11-digit) |
|---|---|---|---|---|---|
| Deferasirox | Deferasirox 360 mg/1 | TabletOral | AvKARE | 73190-052 | 73190-0052-30 |
| Deferasirox | Deferasirox 90 mg/1 | GranuleOral | Aurobindo Pharma Limited | 59651-447 | 59651-0447-30 |
| Deferasirox | Deferasirox 180 mg/1 | GranuleOral | Aurobindo Pharma Limited | 59651-448 | 59651-0448-30 |
| Deferasirox | Deferasirox 360 mg/1 | GranuleOral | Aurobindo Pharma Limited | 59651-449 | 59651-0449-30 |
| Deferasirox | Deferasirox 125 mg/1 | Tablet, For suspensionOral | Teva Pharmaceuticals, Inc. | 0480-7011 | 00480-7011-56 |
| Deferasirox | Deferasirox 250 mg/1 | Tablet, For suspensionOral | Teva Pharmaceuticals, Inc. | 0480-7012 | 00480-7012-56 |
| Deferasirox | Deferasirox 500 mg/1 | Tablet, For suspensionOral | Teva Pharmaceuticals, Inc. | 0480-7013 | 00480-7013-56 |
| Deferasirox | Deferasirox 360 mg/1 | Tablet, Film coatedOral | Aurobindo Pharma Limited | 59651-412 | 59651-0412-30 |
| Deferasirox | Deferasirox 90 mg/1 | Tablet, Film coatedOral | Aurobindo Pharma Limited | 59651-410 | 59651-0410-30 |
| Deferasirox | Deferasirox 180 mg/1 | Tablet, Film coatedOral | Aurobindo Pharma Limited | 59651-411 | 59651-0411-30 |
Other NDCs under ANDA 216229
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Deferasirox | Deferasirox 90 mg/1 | GranuleOral | Camber Pharmaceuticals, Inc. | 31722-029 |
| Deferasirox | Deferasirox 180 mg/1 | GranuleOral | Camber Pharmaceuticals, Inc. | 31722-030 |